SwePub
Sök i LIBRIS databas

  Extended search

L773:1462 0332 OR L773:1460 2172
 

Search: L773:1462 0332 OR L773:1460 2172 > (2010-2014) > Long-term follow-up...

Long-term follow-up in lupus nephritis patients treated with rituximab : clinical and histopathological response

Jónsdóttir, Thórunn (author)
Department of Medicine, Rheumatology Unit, arolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Zickert, Agneta (author)
Karolinska Institutet
Sundelin, Birgitta (author)
Karolinska Institutet
show more...
Henriksson, Elisabet Welin, 1960- (author)
Karolinska Institutet
van Vollenhoven, Ronald F. (author)
Karolinska Institutet
Gunnarsson, Iva (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2013-01-03
2013
English.
In: Rheumatology. - : Oxford University Press. - 1462-0324 .- 1462-0332. ; 52:5, s. 847-855
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • OBJECTIVE: To investigate the long-term clinical, histological and serological affects of B-cell-depleting therapy (BCDT) in patients with LN refractory to conventional treatment.METHODS: Twenty-five patients, followed for a mean time of 36 months (9-95 months), were included. Renal disease activity was evaluated with the BILAG index and renal response was determined according to the LN European consensus statement. Renal biopsies were performed for histological evaluation at baseline and follow-up.RESULTS: Partial response (PR) or complete renal response (CR) was observed in 22 of 25 after a median of 12 months. Sixteen patients achieved CR after a median of 24 months. Six patients experienced a renal relapse. Proteinuria decreased significantly (P = 0.0002) from baseline to 36 months. A noteworthy histological improvement was seen in nearly all patients with a significant reduction in activity index (P = 0.01). Longer depletion time and low baseline values of IgM were indicative of achieving clinical remission during the first year after treatment (P = 0.03 and P = 0.04, respectively).CONCLUSION: In therapy-resistant LN, BCDT induced clinical and histological improvements in the majority of patients. Transition from PR to CR was mainly seen during the second year of follow-up. Patients with longer depletion time and low baseline levels of IgM were more likely to gain a faster remission, suggesting that the clinical benefit may be linked to suppression of autoreactive plasmablasts. Although formal evidence of BCDT in LN is lacking, our data may provide guidance to clinicians considering therapeutic options in patients with refractory LN.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view